Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/1/2018
SIETES contiene 92186 citas

 
 
 1 a 20 de 134 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
2. Cita con resumen
Anónimo. Sacubitril/valsartan (Entresto) for heart failure. Med Lett Drugs Ther 2015;57:107-9. [Ref.ID 99650]
3. Cita con resumen
Kelley KK. New heart failure drug combo approved. Journal Watch 2015:1. [Ref.ID 99246]
4. Cita con resumen
Bas M, Greve J, Stelter K, Havel M, Strassen U, Rotter N, Veit J, Schossow B, Hapfelmeier A, Kehl V, Kojda G, Hoffmann TK. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 2015;372:418-25. [Ref.ID 98747]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Jessup M, Komajda FM, McMurray JJV, Packer M. Perspective roundtable: PARADIGM-HF - The experts' discussion. N Engl J Med 2014;371:e15. [Ref.ID 98475]
6. Cita con resumen
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, for the PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. [Ref.ID 98005]
7. Cita con resumen
Anónimo. Over-the-counter topical acne products: drug safety communication - Rare but serious hypersensitivity reactions. FDA U.S. Food and Drug Administration 2014:25 de junio. [Ref.ID 97713]
8. Cita con resumen
Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]
10.Tiene citas relacionadas Cita con resumen
Toh S, Reichman ME, Houstoun M, Southworth MR, Ding X, Hernandez AF, Levenson M, Li L, McCloskey C, Shoaibi A, Wu E, Zomberg G, Hennessy S. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012;172:1582-9. [Ref.ID 94053]
11. Cita con resumen
Anónimo. Vildagliptin – a new oral antidiabetic agent. Signal 2011:13-4. [Ref.ID 91692]
12. Cita con resumen
Anónimo. Conestt alfa. Juste un autre mode de production. Prescrire 2011;31:734. [Ref.ID 91599]
13.
Scheirey CD, Scholz FJ, Shortsleeve MJ, Katz DS. Angiotensin-converting enzyme inhibitor-induced small-bowel angioedema: clinical and imaging findings in 20 patients. AJR Am J Roentgenol 2011;197:393-8. [Ref.ID 91002]
14. Cita con resumen
Anónimo. Prasugrel (Efient?): rare but serious hypersensitivity reactions. Drug Safety Update 2011;4:A1. [Ref.ID 90622]
15.Enlace a cita originalTiene citas relacionadas
Thong BYH, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011;71:684-700. [Ref.ID 90601]
16.Enlace a cita originalTiene citas relacionadas
Arden-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol 2011;71:672-83. [Ref.ID 90600]
17.Enlace a cita originalTiene citas relacionadas
Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol 2011;71:659-71. [Ref.ID 90599]
18.Enlace a cita originalTiene citas relacionadas
Nel L, Eren E. Peri-operative anaphylaxis. Br J Clin Pharmacol 2011;71:647-58. [Ref.ID 90598]
19.Enlace a cita originalTiene citas relacionadas
Frew A. General principles of investigating and managing drug allergy. Br J Clin Pharmacol 2011;71:642-6. [Ref.ID 90597]
20.Tiene citas relacionadas Cita con resumen
Waller DG. Allergy, pseudo-allergy and non-allergy. Br J Clin Pharmacol 2011;71:637-8. [Ref.ID 90595]
Seleccionar todas
 
 1 a 20 de 134 siguiente >>